# Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia

Source: https://onco.cc/trials/nct04684147/  
OnCo record `nct04684147` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of single dose of CNCT19 in acute lymphoblastic leukaemia, run by Juventas Cell Therapy Ltd., now recruiting.

## Summary

Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia is a phase 2 interventional study registered as NCT04684147 by Juventas Cell Therapy Ltd., with 100 participants planned, started 2020-12-24 and due to reach its primary completion in 2022-09-22. Interventions recorded: single dose of CNCT19.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04684147
- Phase: 2
- Setting: Phase Ⅱ Clinical Trial of CNCT19 Cell Injection in the Treatment of CD19 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia
- Sponsor: Juventas Cell Therapy Ltd.
- Enrolled: 100

## Sources

- ClinicalTrials.gov NCT04684147: https://clinicaltrials.gov/study/NCT04684147

## Connected records

- cancers: [Acute lymphoblastic leukaemia](https://onco.cc/cancers/all-leukemia/)

---
JSON: https://onco.cc/api/v1/entities/nct04684147.json